Johnson Booster 85% Effective Against Omicron: South Africa Study

The New Diplomat
Writer

Ad

Arise IIP raises $700m in Africa infrastructure deal, welcomes Saudi Vision Invest as shareholder

By Obinna Uballa Arise Integrated Industrial Platforms (Arise IIP), a pan-African developer and operator of industrial zones, has secured $700 million in fresh capital, marking one of the largest private infrastructure transactions in Africa. The deal, announced Wednesday in Dubai, sees Saudi Arabia’s Vision Invest join as a new shareholder alongside founding investors such as…

2027: INEC Grants Official Recognition to Atiku, Obi, Aregbesola, Amaechi, David Mark’s ADC

By Abiola Olawale The Independent National Electoral Commission (INEC) has formally recognized the African Democratic Congress (ADC) under the leadership of former President of the Senate, David Mark. This endorsement positions the party as a key contender ahead of the 2027 general elections. The confirmation was displayed on the website of INEC and sighted by…

Attempted suicide no longer a crime: FG sets December deadline for decriminalisation

By Obinna Uballa The Federal Government has reaffirmed its resolve to decriminalise attempted suicide in Nigeria, setting December 2025 as the deadline for completing the reform. Coordinating Minister of Health and Social Welfare, Prof. Muhammad Pate, disclosed this on Wednesday at a press briefing in Abuja to mark the 2025 World Suicide Prevention Day, themed…

Ad

AFP — A booster of US coronavirus vaccine Johnson & Johnson was 85 percent effective in preventing serious illness in areas where Omicron was dominant, a South African trial study indicated Thursday.

The South African Medical Research Council conducted the study on health workers from November 15 to December 20, but it has still not been peer-reviewed.

It found the top-up jab to largely protect staff in a country where the highly transmissible strain is now behind most Covid cases.

“Data from the… study confirm that the Johnson & Johnson COVID-19 booster shot provides 85 percent effectiveness against hospitalization in areas where Omicron is dominant,” Johnson & Johnson said.

“This adds to our growing body of evidence which shows that the effectiveness of the Johnson & Johnson Covid-19 vaccine remains strong and stable over time, including against circulating variants such as Omicron and Delta,” it said.

Around half a million South African health staff have received Johnson jabs as part of clinical trials.

Africa’s hardest-hit country, South Africa has recorded more than 3.4 million cases and 90,000 deaths since the start of the pandemic.

An earlier South African study in December found the Pfizer/BioNTech vaccine to be less effective overall against Omicron, but still prevented hospital admissions by up to 70 percent.

Ad

Unlocking Opportunities in the Gulf of Guinea during UNGA80
X whatsapp